Pfizer agrees to update Chantix warnings

Share this article:

Two months after the FDA issued a safety alert on Pfizer's Chantix, the company in January agreed to update labeling to warn patients about the potential for serious neuropsychiatric symptoms.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.